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ABSTRACT 
Objectives: To assess the prevalence, the change and the determinants of change in polypharmacy in a 
population-based sample. 
Methods: Baseline (2003-06) and follow-up (2009-12) data from 4679 participants aged between 35 and 
75 years (53.5% women, mean age 52.6 ± 10.6 years) from the population of Lausanne, Switzerland. 
Polypharmacy was defined by the regular use of ≥5 drugs. Four categories of change were defined: 
never (no polypharmacy at baseline and follow-up), initiating (no polypharmacy at baseline but at 
follow-up), maintaining or quitting. 
Results: Polypharmacy increased from 7.7% at baseline to 15.3% at follow-up. Cardiovascular drugs 
were the most prescribed medicines at baseline and follow up. Gender, age, obesity, smoking, 
previously diagnosed hypertension or diabetes or dyslipidemia   were significantly and independently 
associated with initiating and maintaining polypharmacy.  
Conclusion: In a population-based sample, prevalence of polypharmacy doubled over a 5.6 year period. 
The main determinants of initiating polypharmacy were age, overweight and obesity, smoking status 
and previous diagnosed cardiovascular risk factors. 
Abstract word count: 159 
Keywords: polypharmacy; determinants; trends; general population; Switzerland 
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INTRODUCTION  
In recent years, there has been a substantial increase in the prescribing of regular medicines in 
general populations.[1] Subsequently, prevalence of polypharmacy, referred as the simultaneous intake 
of five or more medications, has been increasing [2] not only among the elderly but also in other ages. 
[3] 
Polypharmacy is driven by the increase in age and multimorbidity. [4] Given the current ageing 
of the population and the number of drugs needed to treat age-associated multimorbidity, it is expected 
that the prevalence of patients on polypharmacy will continue to increase. Polypharmacy can increase 
the risk of drug-disease interaction in addition to drug-drug interactions; however, polypharmacy may, 
in many cases such as multimorbidity, be entirely appropriate and inevitable.[5-7]  
Although polypharmacy has become more widespread in recent years, determinants of change 
in polypharmacy status in longitudinal study are not well studied. Thus, this study aimed 1) to assess the 
prevalence and the change of polypharmacy and 2) to examine the determinants of change in 
polypharmacy status as initiation or quitting.  
 
MATERIALS AND METHODS  
Study population and design 
The Colaus study is an ongoing prospective survey investigating the biological and genetic 
determinants of cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in the population of 
Lausanne, Switzerland. The study was approved by the Institutional Ethics Committee of the University 
of Lausanne (decision reference 33/09). Detailed descriptions of the study design have been reported 
elsewhere.[8] A simple, non-stratified random sample of the Lausanne population aged between 35 and 
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75 years was drawn. Inclusion criteria were: (a) written informed consent and (b) willingness to take part 
in the examination and to provide blood samples. Recruitment began in June 2003 and ended in May 
2006 and included 6733 participants, with a participation rate of 41%. The baseline evaluation included 
an interview, a physical exam, blood sampling and a set of questionnaires. As illustrated in supplemental 
figure 1, of the initial 6733 participants, 6184 (91.8%) provided extended data on their medicines. The 
follow-up visit was similar to the baseline evaluation and was performed between April 2009 and 
September 2012, five and a half years on average after the baseline, and included 5064 participants 
(75.2% of the initial sample), 4679 of which (69.5% of the initial sample) had complete medication data 
at baseline and follow-up. 
 
Lifestyle, clinical and biological parameters 
Lifestyle factors, CVD and medication status were assessed by questionnaire. Smoking status 
was categorized into never, former and current as reported. Educational level was categorized as low 
(obligatory school or apprenticeship), medium (high school), or high (university degree). Height and 
weight were assessed with the participants in light clothes and without shoes using a Seca® scale; body 
mass index (BMI) was categorized as normal (18.5< BMI <25 kg/m2), overweight (25≤ BMI <30 kg/m2) 
and obese (≥30 kg/m2). As the number of underweight (BMI≤ 18.5 kg/m2) participants was small, they 
were included in the normal weight group. 
Blood pressure was measured thrice on the right arm, after a rest of at least 10 minutes in the 
seated position using an Omron® HEM-907 automated oscillometric sphygmomanometer. The average 
of the last two blood pressure measurements was used for analyses.  
Venous blood samples were drawn after an overnight fast. Clinical chemistry assays were 
performed at the central laboratory of the University Hospital of Lausanne (CHUV). Total cholesterol, 
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HDL-cholesterol, triglycerides (TG) and glucose were measured using commercial reagents; LDL-C was 
calculated using the Friedewald formula if TG <4.6mmol/l.  
For each condition (hypertension, dyslipidemia, or diabetes), three categories were defined: 1) 
absent (neither reported nor newly diagnosed at the baseline examination); 2) reported by the 
participant and 3) newly diagnosed at the baseline examination among participants not reporting the 
condition (supplemental figure 2). Newly diagnosed hypertension was defined as a systolic BP (SBP) 
≥140 mm Hg and/or a diastolic BP (DBP) ≥90 mm Hg.[9] Newly diagnosed dyslipidemia was defined as a 
total cholesterol>6.5 mmol/L and/or LDL-cholesterol >4.1 mmol/L and/or triglycerides>2.0 mmol/L.[10] 
Newly diagnosed diabetes was defined as a fasting plasma glucose >7 mmol/L.[11] 
 
Definitions of polypharmacy, and polypharmacy changing status 
Participants indicated which medicines they were currently taking. Medicines were coded 
according to the Anatomical Therapeutics Chemical (ATC) Classification System of the World Health 
Organization. Medicines were considered if they existed in the ATC; only medications listed in the 
official Swiss pharmacopeia (compendium.ch) were considered. Other complementary medicines such 
as non-official phytotherapies, dietary supplements (i.e. shark cartilage, Bach’s flowers) or homeopathy 
were not considered. Polypharmacy was defined as the use of 5 or more medicines, including OTC drugs, 
regardless if a medicine contained one or more effective drugs (i.e. fixed dose combinations).[12]  
Changing of polypharmacy status was defined as never (no polypharmacy at baseline and 
follow-up); initiation (no polypharmacy at baseline but at follow-up); quitting (polypharmacy at baseline 
but not at follow-up) and maintaining (polypharmacy at baseline and follow-up). 
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Statistical analysis 
Statistical analysis was performed using Stata software version 14.1 (Stata Corp, College Station, 
TX, USA). Descriptive results were expressed as mean ± standard deviation (SD) or as number of 
participants (percentage). Bivariate analysis was performed using chi square test for categorical 
variables and Kruskal Wallis nonparametric test for age. Multivariate analysis was performed using 
multinomial (polytomous) logistic regression and results were expressed as multivariate-adjusted 
relative risk ratios (RRR) and [95% confidence interval (CI)]. Models were adjusted for gender; age 
groups ([35-50[; [50-65[ and [65-75]); BMI categories (normal, overweight and obese); educational level 
(low, middle, high); marital status (living in couple, living alone); country of birth (Switzerland vs. other); 
smoking categories (never, former, current); being physically active (yes vs. no); hypertension (never, 
previous and newly diagnosed); dyslipidemia (never, previous and newly diagnosed) and diabetes 
(never, previous and newly diagnosed). Statistical significance was considered for a two-tailed test with 
p<0.05. 
As some drugs could combine several pharmacologically different active substances, we ran  
several sensitivity analyses by checking ATC codes corresponding to combinations of different active 
substances (supplementary table 1), excluding combinations of vitamins and minerals (ATC codes A11A; 
A11C; A11D; A11E; A11G¸ A11J; A12AX; B03AD and B03AE). As ATC codes were defined with a maximum 
of 5 letters in the baseline survey, the same categorization was applied in the follow-up. Categories of 
“polyactive substances” were defined similarly to polypharmacy, i.e. 0-4 and 5 or more active 
substances. The same procedure was applied to define categories of change in polyactive substances: 
never (no polyactive substances at baseline and follow-up); initiation (no polyactive substances at 
baseline but at follow-up); quitting (polyactive substances at baseline but not at follow-up) and 
maintaining (polyactive substances at baseline and follow-up). Age-adjusted analyses were conducted 
using standardization based on the Lausanne population distribution for 2003, obtained from the 
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Canton statistical office http://www.stat.vd.ch/Default.aspx?DocID=7818&DomId=2783. As some age 
groups initially present at baseline no longer existed at follow-up, calculations were based on age range 
40-75, which is common for both baseline and follow-up periods. As no information was available 
regarding the total number of comorbidities, we used the number of medicines at baseline (categorized 
into three groups: 0-1, 2-3 and 4 or more) as a proxy for adjustment. Two analyses were performed: one 
on polypharmacy, and another on polyactive substances. 
 
RESULTS  
Selection and characteristics of participants  
The demographic, clinical and functional characteristics of the participants included and 
excluded are summarized in Supplemental table 2. Excluded participants were more frequently men, 
not born in Switzerland, obese, current smokers and with lower education. 
Prevalence of medicines and polypharmacy 
Prevalences of polypharmacy status and of the main drugs at baseline and follow-up (FU) are 
summarized in table 1. Polypharmacy increased from 7.7% at baseline to 15.3% at follow-up. 
Cardiovascular drugs were the most prescribed medicines, both at baseline and follow-up; among 
cardiovascular drugs, hypolipidemic drugs and statins were the most frequent ones. 
 
Changes and determinants in polypharmacy status 
The changes in the polypharmacy status and determinants of changes are presented in 
Supplemental table 3 (bivariate analysis) and Table 2 (multivariate analysis). Four hundred fifteen 
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participants (9.6%) initiated; 263 (5.6%) maintained and only 97 (2.1%) quitted polypharmacy, while 
3868 (82.7%) were not on polypharmacy neither at baseline nor at follow-up. 
Bivariate analysis showed gender, age, BMI categories, education level, living alone, smoking 
status and known hypertension, dyslipidemia and diabetes to be associated with a change in 
polypharmacy status. Multivariate analysis indicated that being male and older were associated with any 
change in polypharmacy status, while overweight and obesity were only associated with initiation and 
maintaining polypharmacy status. Smoking (current or former) was associated with the initiation of 
polypharmacy; but only current smoking was associated with maintaining polypharmacy status. Known 
hypertension was associated with initiating and maintaining polypharmacy status, while no association 
was found with hypertension diagnosed at baseline. Known dyslipidemia was associated with 
maintaining polypharmacy status, while no association was found with dyslipidemia diagnosed at 
baseline. Both known diabetes and diabetes diagnosed at baseline were associated with initiating or 
maintaining polypharmacy status. 
 
Sensitivity analyses 
The crude prevalence rates of polyactive substance use were 8.9% and 17.1% at baseline and 
follow-up, respectively. The corresponding age-standardized rates for polypharmacy were 8.6% at 
baseline and 9.6% at follow-up; for polyactive substances, the rates were 9.9% and 13.9%, respectively. 
The results of the multivariate analysis using change in polyactive substances are provided in 
supplementary table 4. Similar associations were found as for polypharmacy.  
When the analysis was adjusted for number of medicines at baseline, similar results were 
obtained for polypharmacy regarding the determinants of initiation; for maintenance, significant 
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associations persisted for age, BMI categories and known hypertension, dyslipidemia and diabetes, 
while for quitting all determinants were no longer significant (supplementary table 5). Finally, for 
polyactive substances, most determinants of initiation remained significant; for maintenance, significant 
associations persisted for age, BMI categories and and known hypertension and diabetes, while for 
quitting all determinants were no longer significant (supplementary table 6). 
 
DISCUSSION 
 In this study, we assessed the baseline determinants of changes in polypharmacy such as BMI, 
smoking, and presence of specific comorbidities and we found an absolute increase from 7.7% to 15.3% 
in polypharmacy over 5.6 years. 
 
Prevalence of medicines and polypharmacy  
Cardiovascular drugs were the most prescribed medicines, both at baseline and follow-up. This 
finding is consistent with a study in a Scottish primary care population. [13] Indeed, cardiovascular drugs 
not only constitute the greatest part of medicines taken by the population, but are also a strong 
predictor of polypharmacy.[14] 
Among cardiovascular drugs, hypolipidemic drugs and statins were the most frequent ones and 
their prevalence almost doubled between baseline and follow-up. Importantly, this increase in 
hypolipidemic drugs is lower than the increase in dyslipidaemia prevalence. [15] Nevertheless, this 
doubling of hypolipidemic drugs between baseline and follow-up, with one-fifth of participants taking 
them, is in line with a study conducted in Ireland [1] and also with a wider acceptance of preventive 
medication for the general population.[16] Contrary to United States, there is no consensus regarding 
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guidelines for cardiovascular prevention In Switzerland. Several equations are used. This lack of 
consensus could explain a lower statin prescription.[17]  
 
Changes and determinants in polypharmacy status 
Polypharmacy literally doubled from 7.7% at baseline to 15.3% at follow-up, a finding also 
observed in the US (8.2% in 1999-2000 to 15% in 2011-2012).[18] Although some participants quitted 
polypharmacy, initiating polypharmacy was more than 4.5 fold more frequent than quitting. Male 
gender was significantly associated with a lower likelihood of initiating, quitting or maintaining 
polypharmacy. A possible explanation is that men utilize less frequently preventive care services than 
women,[19] which would preclude the timely detection of diseases and therefore their treatment. 
Nevertheless, the effect of gender in polypharmacy changes should be further explored. 
Increased age was significantly and positively associated with initiating, quitting or maintaining 
polypharmacy. The increased age-related morbidity is the most obvious explanation for the initiation 
and maintenance, while the avoidance of any possible drug-drug interaction as well as the limited life 
expectancy in older adults might explain the positive association with quitting, as discussed in a 
systematic review.[20] 
Increased body mass index and current smoking were significantly and positively associated with 
initiating and maintaining polypharmacy status. Also, similar to our finding, obese subjects had 
significantly more exposure to multiple drug treatments in population-based studies in Italy and 
Greece.[21,22] This might be partly due to the increased number of cardiovascular risk factors among 
obese subjects [23], although other diseases such as arthrosis and sleep disorders might also contribute 
to the increased number of drugs in this group. Regarding smoking, in the Greek study, smokers were 
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almost three times more likely to take four or more drugs.[22] Again, a higher prevalence of smoking-
associated diseases such as chronic obstructive pulmonary disease might contribute. Unfortunately, no 
data regarding non-cardiovascular diseases was collected in the CoLaus study to confirm these 
hypotheses.The most likely explanation is an increased occurrence of obesity- and smoking-associated 
pathologies and corresponding medication. Overall, our results suggest that quitting smoking and 
preventing obesity might be interesting solutions to decrease the prevalence of polypharmacy. 
Consistent with the high prevalence of cardiovascular drugs, participants previously diagnosed 
with hypertension, dyslipidemia and diabetes had a higher likelihood of initiating or maintaining 
polypharmacy status. Similarly, a study conducted in Spain showed that hypertension or dyslipidemia, 
combined with other medications for the treatment of diabetes or other cardiovascular pathologies, 
could be considered as a pattern of polypharmacy.[24] However, newly diagnosed risk factors had no 
effect (with the exception of newly diagnosed diabetes for initiation of polypharmacy). The association 
with maintenance of polypharmacy was expected, as cardiovascular risk factors need a chronic, lifetime 
treatment.[25] The fact that existing cardiovascular risk factors were also associated with initiating 
polypharmacy was less expected, but consistent with the fact that treatment escalation is frequently 
necessary to maintain acceptable levels. Conversely, only newly diagnosed diabetes was significantly 
associated with initiating polypharmacy, which is consistent with a longitudinal study in Netherlands 
indicating diabetes was a strong predictor of polypharmacy.[26] Interestingly, most of the factors 
associated with polypharmacy (obesity, hypertension, dyslipidemia and diabetes) are components of the 
metabolic syndrome. Hence, our results suggest that participants with metabolic syndrome would be at 
high risk of polypharmacy. Indeed, a cross-sectional study conducted in Nancy (France) showed people 
with metabolic syndrome to have a 3.17 higher likelihood of presenting with polypharmacy (≥4 
drugs).[27] 
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Sensitivity analyses 
A significant number of drugs contain several active substances, a sensitivity analysis was 
conducted taking into account the number of active substances rather than the number of drugs (pills) 
taken. Considering only number of drugs might underestimate the effect of polypharmacy and indeed, 
the prevalence rate of participants taking at least 5 active substances was higher by approximately 2% 
than the rate based on drugs. Hence, it is likely that most prevalence rates reported using number of 
drugs (pills) are also underestimated, but the magnitude of the underestimation will depend on the 
availability of drugs with several active substances. 
Interestingly, the main determinants of change in the number of active substances were similar 
to those for polypharmacy. The same findings were obtained after adjusting for number of medicines at 
baseline; for instance, age, BMI categories and known cardiovascular risk factors were positively 
associated with initiation and maintenance. Hence, our results suggest that, contrary to the prevalence 
rates, the determinants of polypharmacy and of polyactive substances are identical and that age and 
BMI categories are the main drivers of initiating and maintaining polypharmacy or polyactive 
substances. Given the ageing and the increase in BMI of the worldwide population, our results suggest 
that the prevalence of polypharmacy or polyactive substances will considerably increase in the near 
future. Still, studies assessing both polypharmacy and polyactive drugs in the general population are 
missing and it would be of interest that our results be replicated in other settings. 
Strengths and limitations 
The major strength of this study is that it is one of the few prospective studies assessing 
determinants of change in polypharmacy in a population-based sample. This study has also some 
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limitations. First, participation rate was low (41%), but in line with other epidemiological studies. [28] 
Second, recall bias might occur, as participants might have indicated only the most important 
medications. Hence, polypharmacy prevalences might be underestimated. Still, our results provide a 
conservative estimation of the already considerable prevalence (15% at follow-up) of polypharmacy in 
this group. Also, recent studies suggest that self-reported medication use closely relates with pharmacy 
records [29]; hence, recall bias might be reduced. 
 
Conclusion 
In a population-based sample, prevalence of polypharmacy doubled over a 5.6 year period. The 
main determinants of initiating polypharmacy were age, overweight and obesity, smoking status and 
previous diagnosed cardiovascular risk factors. 
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TABLES 
Table 1: evolution of polypharmacy status and of the main drugs at baseline (2003-2006) and follow-up (2009-2012), Colaus study, Switzerland, 
4679 participants 
 
 Baseline Follow-up P-value 
Polypharmacy    
5+ medicines 360 (7.7) 714 (15.3) <0.001 
Cardiovascular 1,015 (21.7) 1,780 (38.0) <0.001 
Hypolipidemic drugs (C10) 535 (11.4) 1,003 (21.4) <0.001 
Statins (C10AA, C10B) 459 (9.8) 838 (17.9) <0.001 
Other § 99 (2.1) 216 (4.6) <0.001 
Antivitamin K (B01AA) 52 (1.1) 109 (2.3) <0.001 
Antiaggregants 312 (6.7) 565 (12.1) <0.001 
Aspirin 301 (6.4) 520 (11.1) <0.001 
ARB (C09C, C09D) 238 (5.1) 623 (13.3) <0.001 
ACE inhibitors (C09A, C09B) 157 (3.4) 345 (7.4) <0.001 
Beta-blockers (C07) 163 (3.5) 426 (9.1) <0.001 
Calcium channel blockers (C08) 91 (1.9) 218 (4.7) <0.001 
Diuretics (C03) 55 (1.2) 163 (3.5) <0.001 
Other (C01, C02, C04) 6 (0.1) 81 (1.7) <0.001 
Antidiabetic drugs (A10) 151 (3.2) 265 (5.7) <0.001 
Oral antidiabetics 139 (3.0) 241 (5.2) <0.001 
Insulin (A10A) 27 (0.6) 61 (1.3) <0.001 
Drugs for the digestive tract 284 (6.1) 453 (9.7) <0.001 
Antiacids (A02) 194 (4.2) 341 (7.3) <0.001 
Drugs for constipation (A06) 31 (0.7) 66 (1.4) <0.001 
Other §§ 97 (2.1) 107 (2.3) 0.450 
Vitamins and minerals (A11,A12) 217 (4.6) 596 (12.7) <0.001 
Analgesics 588 (12.6) 625 (13.4) 0.230 
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Anilides (N02BE) 77 (1.7) 106 (2.3) 0.025 
NSAIDs (M01) 225 (4.8) 425 (9.1) <0.001 
Opioids (N02A) 28 (0.6) 61 (1.3) <0.001 
Psychiatric 610 (13.0) 770 (16.5) <0.001 
Antidepressants (N06) 429 (9.2) 503 (10.8) <0.001 
Anxiolytics (N05B) 178 (3.8) 243 (5.2) <0.001 
Hypnotics and sedatives (N05C) 130 (2.8) 227 (4.9) <0.001 
Antipsychotics (N05A) 41 (0.9) 53 (1.1) 0.104 
§§ codes A01, A03, A04, A05, A07 and A09. ARB, angiotensin receptor blockers; ACE, angiotensin converting enzyme; NSAID, non-steroidal anti-
inflammatory drugs; Results are expressed as number of participants (column percentage). Between-period comparison using Cochran’s test for 
paired data. 
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Table 2: multivariate analysis of the factors associated with changes in polypharmacy (5+ medicines/day) status between baseline (2003-2006) 
and follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
 Initiation P-value Quitting P-value Maintenance P-value 
Gender       
Woman 1 (ref)  1 (ref)  1 (ref)  
Man 0.46 (0.36 - 0.59) <0.001 0.34 (0.21 - 0.57) <0.001 0.50 (0.36 - 0.69) <0.001 
Age group       
[35-50[ 1 (ref)  1 (ref)  1 (ref)  
[50-65[ 2.54 (1.93 - 3.34) <0.001 2.53 (1.51 - 4.24) <0.001 4.70 (2.91 - 7.61) <0.001 
[65-75] 4.65 (3.36 - 6.43) <0.001 3.58 (1.86 - 6.88) <0.001 8.96 (5.34 - 15.05) <0.001 
p-value for trend <0.001  <0.001  <0.001  
BMI categories       
Normal 1 (ref)  1 (ref)  1 (ref)  
Overweight 1.70 (1.32 - 2.18) <0.001 1.16 (0.73 - 1.85) 0.535 1.43 (1.00 - 2.04) 0.047 
Obese 1.92 (1.41 - 2.63) <0.001 1.08 (0.55 - 2.13) 0.824 1.96 (1.31 - 2.93) 0.001 
p-value for trend <0.001  0.577  <0.001  
Education       
High 1 (ref.)  1 (ref.)  1 (ref.)  
Middle 1.06 (0.75 - 1.51) 0.743 0.98 (0.53 - 1.82) 0.952 1.97 (1.12 - 3.45) 0.018 
Low 1.13 (0.83 - 1.55) 0.433 0.87 (0.49 - 1.53) 0.630 1.91 (1.13 - 3.21) 0.015 
p-value for trend 0.433  0.497  0.071  
Marital status       
Living alone 1 (ref)  1 (ref)  1 (ref)  
Living in couple 0.92 (0.74 - 1.15) 0.481 0.67 (0.44 - 1.02) 0.059 0.83 (0.62 - 1.12) 0.222 
Born in Switzerland       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 1.02 (0.81 - 1.29) 0.858 0.85 (0.55 - 1.31) 0.462 0.74 (0.54 - 1.00) 0.049 
Smoking status       
Never 1 (ref)  1 (ref)  1 (ref)  
Former 1.56 (1.21 - 2.01) 0.001 1.40 (0.88 - 2.24) 0.152 1.33 (0.96 - 1.86) 0.088 
Current 2.22 (1.69 - 2.91) <0.001 1.08 (0.62 - 1.88) 0.796 1.57 (1.07 - 2.31) 0.020 
p-value for trend <0.001  0.570  0.019  
Physically active       
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No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.91 (0.73 - 1.13) 0.396 0.86 (0.56 - 1.32) 0.490 0.94 (0.70 - 1.26) 0.686 
Hypertension       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 2.71 (2.12 - 3.46) <0.001 1.12 (0.67 - 1.88) 0.654 4.75 (3.39 - 6.65) <0.001 
Diagnosed at baseline 1.28 (0.92 - 1.77) 0.140 0.66 (0.33 - 1.32) 0.240 0.60 (0.32 - 1.14) 0.118 
Dyslipidemia       
None 1 (ref.)  1 (ref.)  1 (ref.)  
Already known 1.40 (1.09 - 1.80) 0.008 1.69 (1.02 - 2.81) 0.043 3.41 (2.43 - 4.77) <0.001 
Diagnosed at baseline 1.03 (0.78 - 1.36) 0.828 1.57 (0.93 - 2.64) 0.091 1.31 (0.85 - 2.02) 0.220 
Diabetes       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 3.35 (2.24 - 5.01) <0.001 1.66 (0.57 - 4.82) 0.350 5.64 (3.68 - 8.65) <0.001 
Diagnosed at baseline 2.62 (1.53 - 4.50) <0.001 1.26 (0.29 - 5.41) 0.753 2.10 (1.03 - 4.30) 0.041 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis using 
polytomous logistic regression using the “never” group as reference and using all variables in the table as covariates. 
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SUPPLEMENTAL DOCUMENTATION 
Supplementary 1 : ATC codes of drugs combining active substances. 
ATC code Designation 
A03C antispasmodics in combination with psycholeptics 
A03D antispasmodics in combination with analgesics 
A03E antispasmodics and anticholinergics in combination with other drugs 
A05C drugs for bile therapy and lipotropics in combination 
C02L antihypertensives and diuretics in combination 
C02N combinations of antihypertensives 
C03E diuretics and potassium-sparing agents in combination 
C07F beta blocking agents, other combinations 
C09B ACE inhibitors, combinations 
C09D angiotensin II antagonists, combinations 
C10B lipid modifying agents, combinations 
D06C antibiotics and chemotherapeutics, combinations 
D07B corticosteroids, combinations with antiseptics 
D07C corticosteroids, combinations with antibiotics 
D07X corticosteroids, other combinations 
G01B antiinfectives/antiseptics in combination with corticosteroids 
G03E androgens and female sex hormones in combination 
G03F progestogens and estrogens in combination 
J01R combinations of antibacterials 
M01B antiinflammatory/antirheumatic agents in combination 
N06C psycholeptics and psychoanaleptics in combination 
R05F cough suppressants and expectorants, combinations 
S01C antiinflammatory agents and antiinfectives in combination 
S02C corticosteroids and antiinfectives in combination 
S03C corticosteroids and antiinfectives in combination 
A10BD combinations of oral blood glucose lowering drugs 
C03AB thiazides and potassium in combination 
C03AH thiazides, combinations with psycholeptics and/or analgesics 
C03AX thiazides, combinations with other drugs 
C03BB sulfonamides and potassium in combination 
C03BK sulfonamides, combinations with other drugs 
C03CB sulfonamides and potassium in combination 
G02AC ergot alkaloids and oxytocin incl. analogues, in combination 
G03AA progestogens and estrogens, fixed combinations 
G03CC estrogens, combinations with other drugs 
J01EE combinations of sulfonamides and trimethoprim, incl. derivatives 
J04AM combinations of drugs for treatment of tuberculosis 
J05AR antivirals for treatment of HIV infections, combinations 
N01AG barbiturates in combination with other drugs 
N02AG opioids in combination with antispasmodics 
N02AJ opioids in combination with non-opioid analgesics 
R03AK adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 
R03AL adrenergics in combination with anticholinergics 
S01BB corticosteroids and mydriatics in combination 
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Supplemental table 2: baseline characteristics of participants included and excluded from the study 
 Included Excluded P-value 
Sample size 4679 2054  
Women (%) 2505 (53.5) 1039 (50.6) 0.025 
Age (years) 52.6 ± 10.6 52.6 ± 11.1 0.979 
Age group (%)   0.017 
[35-50[ 2088 (44.6) 941 (45.8)  
[50-65[ 1930 (41.3) 781 (38.0)  
[65-75] 661 (14.1) 332 (16.2)  
BMI categories (%)   <0.001 
Normal + underweight 2320 (49.6) 917 (44.7)  
Overweight 1706 (36.5) 756 (36.9)  
Obese 653 (14.0) 378 (18.4)  
Education (%)   <0.001 
High 939 (20.1) 381 (18.7)  
Middle 1186 (25.4) 439 (21.5)  
Low 2553 (54.6) 1221 (59.8)  
Living alone (%) 1524 (32.6) 690 (33.7) 0.381 
Born in Switzerland (%) 3164 (67.6) 867 (42.2) <0.001 
Smoking status (%)   <0.001 
Never 1890 (40.4) 842 (41.1)  
Former 1580 (33.8) 603 (29.4)  
Current 1208 (25.8) 604 (29.5)  
Physically active (%) 2690 (57.5) 905 (44.1) <0.001 
Previously diagnosed    
Hypertension 1147 (24.5) 588 (28.6) <0.001 
Dyslipidemia 1087 (23.2) 486 (23.7) 0.701 
Diabetes 205 (4.4) 123 (6.0) 0.005 
 
BMI, body mass index. Results are expressed as number of participants (column percentage) or as mean 
± standard deviation. Between-group comparisons using chi-square for categorical variables and 
student’s t-test for continuous variables 
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Supplemental table 3: bivariate analysis of the factors associated with changes in polypharmacy (5+ medicines/day), between baseline (2003-
2006) and FU (2009-2012), Colaus study, Switzerland, 4679 participants. 
 Never (N=3868) Initiation (N=451) Quitting (N=97) Maintaining (N=263) P-values 
Women (%) 2012 (52.0) 273 (60.5) 73 (75.3) 147 (55.9) <0.001 
Age (years) 51.1 ± 10.2 58.9 ± 9.5 56.7 ± 10.5 62.0 ± 7.9 <0.001 
Age group (%)     <0.001 
[35-50[ 1958 (50.6) 85 (18.9) 23 (23.7) 22 (8.4)  
[50-65[ 1498 (38.7) 235 (52.1) 53 (54.6) 144 (54.8)  
[65-75] 412 (10.7) 131 (29.1) 21 (21.7) 97 (36.9)  
BMI categories (%)     <0.001 
Normal + underweight 2061 (53.3) 145 (32.1) 48 (49.5) 66 (25.1)  
Overweight 1366 (35.3) 198 (43.9) 36 (37.1) 10.6 (40.3)  
Obese 441 (11.4) 108 (24.0) 13 (13.4) 91 (34.6)  
Education (%)     <0.001 
High 841 (21.8) 61 (13.5) 18 (18.6) 19 (7.2)  
Middle 991 (25.6) 103 (22.8) 26 (26.8) 66 (25.1)  
Low 2035 (52.6) 287 (63.6) 53 (54.6) 178 (67.7)  
Living alone (%) 1208 (31.2) 170 (37.8) 45 (46.4) 101(38.4) <0.001 
Born in Switzerland (%) 2608 (67.4) 320 (71.0) 64 (66.0) 172 (65.4) 0.381 
Smoking status (%)     <0.001 
Never 1614 (41.7) 141 (31.3) 38 (39.2) 97 (36.9)  
Former 1262 (32.6) 173 (38.4) 38 (39.2) 107 (40.7)  
Current 991 (25.6) 137 (30.4) 21 (21.7) 59 (22.4)  
Physically active (%) 2261 (58.5) 238 (52.8) 55 (56.7) 136 (51.7) 0.027 
Hypertension     <0.001 
None 2637 (68.2) 173 (38.4) 62 (64.0) 62 (23.6)  
Already known 721 (18.6) 213 (47.2) 25 (25.8) 188 (71.5)  
Diagnosed at baseline 510 (13.2) 65 (14.4) 10 (10.3) 13 (4.9)  
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Dyslipidemia     <0.001 
None 2366 (61.2) 199 (44.1) 45 (46.4) 62 (23.6)  
Already known 739 (19.1) 160 (35.5) 28 (29.9) 160 (60.9)  
Diagnosed at baseline 763 (19.7) 92 (20.4) 24 (24.7) 41 (15.6)  
Diabetes     <0.001 
None 3727 (96.4) 376 (83.4) 91 (93.8) 187 (71.1)  
Already known 85 (2.2) 52 (11.5) 4 (4.1) 64 (24.3)  
Diagnosed at baseline 56 (1.5) 23 (5.1) 2 (2.1) 12 (4.6)  
BMI, body mass index. Results are expressed as number of participants (column percentage) or as mean ± standard deviation. Between-group 
comparisons using chi-square for categorical variables and analysis of variance for continuous variables. 
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Supplementary table 4: multivariate analysis of the factors associated with changes in polyactive substances (5+ active substances/day) status 
between baseline (2003-2006) and follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
 Initiation P-value Quitting P-value Maintenance P-value 
N (% total) 404 (8.6)  156 (3.3)  260 (5.6)  
Gender       
Woman 1 (ref)  1 (ref)  1 (ref)  
Man 0.59 (0.46 - 0.75) <0.001 0.31 (0.21 - 0.47) <0.001 0.52 (0.37 - 0.72) <0.001 
Age group       
[35-50[ 1 (ref)  1 (ref)  1 (ref)  
[50-65[ 1.85 (1.39 - 2.47) <0.001 3.14 (2.06 - 4.81) <0.001 4.07 (2.47 - 6.71) <0.001 
[65-75] 4.16 (2.98 - 5.81) <0.001 4.13 (2.40 - 7.10) <0.001 10.2 (5.99 - 17.3) <0.001 
p-value for trend <0.001  <0.001  <0.001  
BMI categories       
Normal 1 (ref)  1 (ref)  1 (ref)  
Overweight 1.92 (1.46 - 2.52) <0.001 1.08 (0.75 - 1.58) 0.672 1.69 (1.16 - 2.45) 0.006 
Obese 2.23 (1.61 - 3.10) <0.001 1.03 (0.60 - 1.77) 0.901 2.18 (1.44 - 3.32) <0.001 
p-value for trend <0.001  0.693  <0.001  
Education       
High 1 (ref.)  1 (ref.)  1 (ref.)  
Middle 0.90 (0.60 - 1.34) 0.594 1.07 (0.65 - 1.78) 0.789 1.84 (1.04 - 3.25) 0.036 
Low 1.39 (0.98 - 1.95) 0.063 0.96 (0.60 - 1.53) 0.867 1.78 (1.05 - 3.01) 0.032 
p-value for trend 0.006  0.683  0.117  
Marital status       
Living alone 1 (ref)  1 (ref)  1 (ref)  
Living in couple 0.86 (0.68 - 1.10) 0.226 0.93 (0.66 - 1.30) 0.654 0.74 (0.55 - 1.01) 0.059 
Born in Switzerland       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.91 (0.71 - 1.16) 0.458 0.96 (0.67 - 1.38) 0.845 0.73 (0.53 - 1.00) 0.047 
Smoking status       
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Never 1 (ref)  1 (ref)  1 (ref)  
Former 1.49 (1.14 - 1.96) 0.004 1.15 (0.79 - 1.68) 0.476 1.53 (1.09 - 2.16) 0.014 
Current 2.11 (1.58 - 2.83) <0.001 1.19 (0.78 - 1.82) 0.411 1.68 (1.12 - 2.51) 0.011 
p-value for trend <0.001  0.341  0.007  
Physically active       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.87 (0.69 - 1.10) 0.254 0.91 (0.65 - 1.28) 0.602 0.90 (0.67 - 1.22) 0.495 
Hypertension       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 4.03 (3.10 - 5.25) <0.001 1.58 (1.06 - 2.33) 0.023 8.00 (5.52 - 11.6) <0.001 
Diagnosed at baseline 1.64 (1.16 - 2.32) 0.005 0.62 (0.34 - 1.12) 0.112 0.84 (0.44 - 1.62) 0.603 
Dyslipidemia       
None 1 (ref.)  1 (ref.)  1 (ref.)  
Already known 1.68 (1.30 - 2.19) <0.001 1.43 (0.95 - 2.15) 0.086 3.30 (2.35 - 4.65) <0.001 
Diagnosed at baseline 1.05 (0.78 - 1.42) 0.748 1.36 (0.90 - 2.07) 0.144 1.07 (0.68 - 1.70) 0.764 
Diabetes       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 4.04 (2.67 - 6.10) <0.001 1.44 (0.56 - 3.72) 0.450 6.99 (4.50 - 10.9) <0.001 
Diagnosed at baseline 2.68 (1.55 - 4.65) <0.001 1.62 (0.56 - 4.68) 0.370 1.69 (0.78 - 3.64) 0.182 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis using 
polytomous logistic regression using the “never” group as reference and using all variables in the table as covariates. 
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Supplementary table 5: multivariate analysis of the factors associated with changes in polypharmacy status between baseline (2003-2006) and 
follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
 Initiation P-value Quitting P-value Maintenance P-value 
N (% total) 451 (9.7)  97 (1.9)  263 (5.19)  
Gender       
Woman 1 (ref)  1 (ref)  1 (ref)  
Man 0.59 (0.46 - 0.76) <0.001 0.79 (0.42 - 1.49) 0.471 0.94 (0.59 - 1.49) 0.784 
Age group       
[35-50[ 1 (ref)  1 (ref)  1 (ref)  
[50-65[ 2.00 (1.50 - 2.65) <0.001 1.05 (0.55 - 2.01) 0.884 2.06 (1.08 - 3.91) 0.027 
[65-75] 3.12 (2.22 - 4.39) <0.001 0.96 (0.43 - 2.14) 0.919 2.71 (1.34 - 5.47) 0.005 
p-value for trend <0.001  0.982  0.006  
BMI categories       
Normal 1 (ref)  1 (ref)  1 (ref)  
Overweight 1.65 (1.27 - 2.13) <0.001 1.19 (0.66 - 2.16) 0.559 1.36 (0.83 - 2.22) 0.222 
Obese 1.92 (1.38 - 2.66) <0.001 1.26 (0.55 - 2.92) 0.586 2.16 (1.20 - 3.88) 0.010 
p-value for trend <0.001  0.466  0.006  
Education       
High 1 (ref.)  1 (ref.)  1 (ref.)  
Middle 1.05 (0.73 - 1.51) 0.779 1.02 (0.47 - 2.19) 0.962 2.15 (1.05 - 4.43) 0.037 
Low 1.16 (0.84 - 1.60) 0.368 1.00 (0.50 - 2.01) 1.000 2.32 (1.19 - 4.51) 0.013 
p-value for trend 0.327  0.939  0.031  
Marital status       
Living alone 1 (ref)  1 (ref)  1 (ref)  
Living in couple 0.98 (0.78 - 1.24) 0.872 0.71 (0.43 - 1.19) 0.199 0.95 (0.63 - 1.44) 0.825 
Born in Switzerland       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.99 (0.78 - 1.26) 0.958 0.74 (0.43 - 1.27) 0.276 0.68 (0.44 - 1.04) 0.077 
Smoking status       
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Never 1 (ref)  1 (ref)  1 (ref)  
Former 1.45 (1.11 - 1.88) 0.006 1.02 (0.57 - 1.82) 0.941 1.08 (0.68 - 1.71) 0.738 
Current 2.21 (1.66 - 2.93) <0.001 0.79 (0.40 - 1.58) 0.51 1.50 (0.88 - 2.57) 0.135 
p-value for trend <0.001  0.560  0.223  
Physically active       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.93 (0.74 - 1.16) 0.506 0.99 (0.58 - 1.69) 0.978 1.24 (0.82 - 1.86) 0.310 
Hypertension       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 2.08 (1.61 - 2.70) <0.001 0.58 (0.32 - 1.07) 0.079 2.48 (1.56 - 3.95) <0.001 
Diagnosed at baseline 1.35 (0.97 - 1.90) 0.076 0.94 (0.39 - 2.24) 0.882 0.79 (0.35 - 1.80) 0.573 
Dyslipidemia       
None 1 (ref.)  1 (ref.)  1 (ref.)  
Already known 1.14 (0.88 - 1.49) 0.313 1.15 (0.62 - 2.12) 0.665 2.22 (1.39 - 3.52) 0.001 
Diagnosed at baseline 1.07 (0.80 - 1.43) 0.660 1.63 (0.85 - 3.15) 0.142 1.6 (0.9 - 2.87) 0.112 
Diabetes       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 2.24 (1.46 - 3.42) <0.001 0.58 (0.18 - 1.84) 0.353 2.60 (1.42 - 4.75) 0.002 
Diagnosed at baseline 3.37 (1.91 - 5.95) <0.001 3.71 (0.58 - 23.7) 0.165 4.38 (1.2 - 16.0) 0.025 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis using 
polytomous logistic regression using the “never” group as reference, using all variables in the table as covariates plus the number of medicines 
at baseline. 
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Supplementary table 6: multivariate analysis of the factors associated with changes in polyactive substances (5+ active substances/day) status 
between baseline (2003-2006) and follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
 Initiation P-value Quitting P-value Maintenance P-value 
N (% total) 404 (8.6)  156 (3.3)  260 (5.6)  
Gender       
Woman 1 (ref)  1 (ref)  1 (ref)  
Man 0.57 (0.45 - 0.72) <0.001 0.69 (0.38 - 1.26) 0.224 0.78 (0.49 - 1.26) 0.313 
Age group       
[35-50[ 1 (ref)  1 (ref)  1 (ref)  
[50-65[ 1.78 (1.37 - 2.32) <0.001 1.35 (0.71 - 2.58) 0.360 1.65 (0.89 - 3.05) 0.109 
[65-75] 2.66 (1.92 - 3.68) <0.001 1.25 (0.57 - 2.74) 0.585 2.62 (1.32 - 5.22) 0.006 
p-value for trend <0.001  0.571  0.003  
BMI categories       
Normal 1 (ref)  1 (ref)  1 (ref)  
Overweight 1.64 (1.28 - 2.10) <0.001 1.15 (0.65 - 2.05) 0.631 1.37 (0.83 - 2.27) 0.213 
Obese 2.00 (1.46 - 2.73) <0.001 1.19 (0.54 - 2.63) 0.666 2.07 (1.12 - 3.82) 0.020 
p-value for trend <0.001  0.575  0.014  
Education       
High 1 (ref.)  1 (ref.)  1 (ref.)  
Middle 1.04 (0.73 - 1.48) 0.825 1.25 (0.59 - 2.65) 0.560 1.95 (0.96 - 3.94) 0.064 
Low 1.19 (0.87 - 1.62) 0.274 1.06 (0.53 - 2.10) 0.871 1.80 (0.95 - 3.42) 0.073 
p-value for trend 0.201  0.986  0.166  
Marital status       
Living alone 1 (ref)  1 (ref)  1 (ref)  
Living in couple 1.03 (0.83 - 1.29) 0.773 0.97 (0.59 - 1.59) 0.898 1.08 (0.71 - 1.64) 0.717 
Born in Switzerland       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.97 (0.77 - 1.23) 0.828 0.87 (0.52 - 1.47) 0.600 0.82 (0.53 - 1.28) 0.381 
Smoking status       
Never 1 (ref)  1 (ref)  1 (ref)  
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Former 1.52 (1.18 - 1.95) 0.001 0.88 (0.5 - 1.53) 0.649 1.19 (0.74 - 1.91) 0.465 
Current 2.14 (1.63 - 2.81) <0.001 0.87 (0.45 - 1.7) 0.688 1.81 (1.04 - 3.14) 0.035 
p-value for trend <0.001  0.600  0.057  
Physically active       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.91 (0.73 - 1.13) 0.391 1.03 (0.62 - 1.72) 0.916 1.30 (0.85 - 1.98) 0.224 
Hypertension       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 2.72 (2.13 - 3.49) <0.001 1.34 (0.75 - 2.38) 0.321 4.1 (2.54 - 6.61) <0.001 
Diagnosed at baseline 1.53 (1.11 - 2.10) 0.009 1.28 (0.55 - 2.96) 0.566 0.89 (0.39 - 2.00) 0.769 
Dyslipidemia       
None 1 (ref.)  1 (ref.)  1 (ref.)  
Already known 1.20 (0.93 - 1.54) 0.155 0.74 (0.41 - 1.33) 0.310 1.50 (0.93 - 2.42) 0.100 
Diagnosed at baseline 0.96 (0.72 - 1.27) 0.761 1.15 (0.60 - 2.18) 0.676 1.17 (0.65 - 2.11) 0.609 
Diabetes       
None 1 (ref)  1 (ref)  1 (ref)  
Already known 2.51 (1.64 - 3.83) <0.001 0.60 (0.21 - 1.77) 0.359 2.60 (1.38 - 4.90) 0.003 
Diagnosed at baseline 3.34 (1.92 - 5.81) <0.001 2.22 (0.36 - 13.9) 0.392 3.13 (0.87 - 11.2) 0.080 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis using 
polytomous logistic regression using the “never” group as reference and using all variables in the table as covariates plus the number of 
medicines at baseline. 
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Supplemental figure 1: sampling flowchart 
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Supplemental figure 2: definition of reported and newly diagnosed hypertension. SBP, systolic blood 
pressure; DBP, diastolic blood pressure. The same process was used for dyslipidemia and diabetes  
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Initial sample 
N=6773 
Final sample 
N=4679 (69.5%) 
No follow-up data 
N=1505 (22.3%) 
No medicines 
N=549 (8.2%) 
Supplemental figure 2: definition of reported and newly 
diagnosed hypertension. SBP, systolic blood pressure; DBP, 
diastolic blood pressure. The same process was used for 
dyslipidemia and diabetes 
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Supplementary 1 : ATC codes of drugs combining active substances. 
ATC code Designation 
A03C antispasmodics in combination with psycholeptics 
A03D antispasmodics in combination with analgesics 
A03E antispasmodics and anticholinergics in combination with other drugs 
A05C drugs for bile therapy and lipotropics in combination 
C02L antihypertensives and diuretics in combination 
C02N combinations of antihypertensives 
C03E diuretics and potassium-sparing agents in combination 
C07F beta blocking agents, other combinations 
C09B ACE inhibitors, combinations 
C09D angiotensin II antagonists, combinations 
C10B lipid modifying agents, combinations 
D06C antibiotics and chemotherapeutics, combinations 
D07B corticosteroids, combinations with antiseptics 
D07C corticosteroids, combinations with antibiotics 
D07X corticosteroids, other combinations 
G01B antiinfectives/antiseptics in combination with corticosteroids 
G03E androgens and female sex hormones in combination 
G03F progestogens and estrogens in combination 
J01R combinations of antibacterials 
M01B antiinflammatory/antirheumatic agents in combination 
N06C psycholeptics and psychoanaleptics in combination 
R05F cough suppressants and expectorants, combinations 
S01C antiinflammatory agents and antiinfectives in combination 
S02C corticosteroids and antiinfectives in combination 
S03C corticosteroids and antiinfectives in combination 
A10BD combinations of oral blood glucose lowering drugs 
C03AB thiazides and potassium in combination 
C03AH thiazides, combinations with psycholeptics and/or analgesics 
C03AX thiazides, combinations with other drugs 
C03BB sulfonamides and potassium in combination 
C03BK sulfonamides, combinations with other drugs 
C03CB sulfonamides and potassium in combination 
G02AC ergot alkaloids and oxytocin incl. analogues, in combination 
G03AA progestogens and estrogens, fixed combinations 
G03CC estrogens, combinations with other drugs 
J01EE combinations of sulfonamides and trimethoprim, incl. derivatives 
J04AM combinations of drugs for treatment of tuberculosis 
J05AR antivirals for treatment of HIV infections, combinations 
N01AG barbiturates in combination with other drugs 
N02AG opioids in combination with antispasmodics 
N02AJ opioids in combination with non-opioid analgesics 
R03AK adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 
R03AL adrenergics in combination with anticholinergics 
S01BB corticosteroids and mydriatics in combination 
Supplementary table 4: multivariate analysis of the factors associated with changes in polyactive substances (5+ active substances/day) status 
between baseline (2003-2006) and follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
 Initiation P-value Quitting P-value Maintenance P-value 
N (% total) 404 (8.6)  156 (3.3)  260 (5.6)  
Gender       
Woman 1 (ref)  1 (ref)  1 (ref)  
Man 0.59 (0.46 - 0.75) <0.001 0.31 (0.21 - 0.47) <0.001 0.52 (0.37 - 0.72) <0.001 
Age group       
[35-50[ 1 (ref)  1 (ref)  1 (ref)  
[50-65[ 1.85 (1.39 - 2.47) <0.001 3.14 (2.06 - 4.81) <0.001 4.07 (2.47 - 6.71) <0.001 
[65-75] 4.16 (2.98 - 5.81) <0.001 4.13 (2.40 - 7.10) <0.001 10.2 (5.99 - 17.3) <0.001 
p-value for trend <0.001  <0.001  <0.001  
BMI categories       
Normal 1 (ref)  1 (ref)  1 (ref)  
Overweight 1.92 (1.46 - 2.52) <0.001 1.08 (0.75 - 1.58) 0.672 1.69 (1.16 - 2.45) 0.006 
Obese 2.23 (1.61 - 3.10) <0.001 1.03 (0.60 - 1.77) 0.901 2.18 (1.44 - 3.32) <0.001 
p-value for trend <0.001  0.693  <0.001  
Education       
High 1 (ref.)  1 (ref.)  1 (ref.)  
Middle 0.90 (0.60 - 1.34) 0.594 1.07 (0.65 - 1.78) 0.789 1.84 (1.04 - 3.25) 0.036 
Low 1.39 (0.98 - 1.95) 0.063 0.96 (0.60 - 1.53) 0.867 1.78 (1.05 - 3.01) 0.032 
p-value for trend 0.006  0.683  0.117  
Marital status       
Living alone 1 (ref)  1 (ref)  1 (ref)  
Living in couple 0.86 (0.68 - 1.10) 0.226 0.93 (0.66 - 1.30) 0.654 0.74 (0.55 - 1.01) 0.059 
Born in Switzerland       
No 1 (ref)  1 (ref)  1 (ref)  
Yes 0.91 (0.71 - 1.16) 0.458 0.96 (0.67 - 1.38) 0.845 0.73 (0.53 - 1.00) 0.047 
Smoking status       
Never 1 (ref)  1 (ref)  1 (ref)  
Former 1.49 (1.14 - 1.96) 0.004 1.15 (0.79 - 1.68) 0.476 1.53 (1.09 - 2.16) 0.014 
Current 2.11 (1.58 - 2.83) <0.001 1.19 (0.78 - 1.82) 0.411 1.68 (1.12 - 2.51) 0.011 
p-value for trend <0.001 0.341 0.007 
Physically active 
No 1 (ref) 1 (ref) 1 (ref) 
Yes 0.87 (0.69 - 1.10) 0.254 0.91 (0.65 - 1.28) 0.602 0.90 (0.67 - 1.22) 0.495 
Hypertension 
None 1 (ref) 1 (ref) 1 (ref) 
Already known 4.03 (3.10 - 5.25) <0.001 1.58 (1.06 - 2.33) 0.023 8.00 (5.52 - 11.6) <0.001 
Diagnosed at baseline 1.64 (1.16 - 2.32) 0.005 0.62 (0.34 - 1.12) 0.112 0.84 (0.44 - 1.62) 0.603 
Dyslipidemia 
None 1 (ref.) 1 (ref.) 1 (ref.) 
Already known 1.68 (1.30 - 2.19) <0.001 1.43 (0.95 - 2.15) 0.086 3.30 (2.35 - 4.65) <0.001 
Diagnosed at baseline 1.05 (0.78 - 1.42) 0.748 1.36 (0.90 - 2.07) 0.144 1.07 (0.68 - 1.70) 0.764 
Diabetes 
None 1 (ref) 1 (ref) 1 (ref) 
Already known 4.04 (2.67 - 6.10) <0.001 1.44 (0.56 - 3.72) 0.450 6.99 (4.50 - 10.9) <0.001 
Diagnosed at baseline 2.68 (1.55 - 4.65) <0.001 1.62 (0.56 - 4.68) 0.370 1.69 (0.78 - 3.64) 0.182 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis 
using polytomous logistic regression using the “never” group as reference and using all variables in the table as covariates. 
Supplementary table 5: multivariate analysis of the factors associated with changes in polypharmacy status between baseline (2003-2006) and 
follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
Initiation P-value Quitting P-value Maintenance P-value 
N (% total) 451 (9.7) 97 (1.9) 263 (5.19) 
Gender 
Woman 1 (ref) 1 (ref) 1 (ref) 
Man 0.59 (0.46 - 0.76) <0.001 0.79 (0.42 - 1.49) 0.471 0.94 (0.59 - 1.49) 0.784 
Age group 
[35-50[ 1 (ref) 1 (ref) 1 (ref) 
[50-65[ 2.00 (1.50 - 2.65) <0.001 1.05 (0.55 - 2.01) 0.884 2.06 (1.08 - 3.91) 0.027 
[65-75] 3.12 (2.22 - 4.39) <0.001 0.96 (0.43 - 2.14) 0.919 2.71 (1.34 - 5.47) 0.005 
p-value for trend <0.001 0.982 0.006 
BMI categories 
Normal 1 (ref) 1 (ref) 1 (ref) 
Overweight 1.65 (1.27 - 2.13) <0.001 1.19 (0.66 - 2.16) 0.559 1.36 (0.83 - 2.22) 0.222 
Obese 1.92 (1.38 - 2.66) <0.001 1.26 (0.55 - 2.92) 0.586 2.16 (1.20 - 3.88) 0.010 
p-value for trend <0.001 0.466 0.006 
Education 
High 1 (ref.) 1 (ref.) 1 (ref.) 
Middle 1.05 (0.73 - 1.51) 0.779 1.02 (0.47 - 2.19) 0.962 2.15 (1.05 - 4.43) 0.037 
Low 1.16 (0.84 - 1.60) 0.368 1.00 (0.50 - 2.01) 1.000 2.32 (1.19 - 4.51) 0.013 
p-value for trend 0.327 0.939 0.031 
Marital status 
Living alone 1 (ref) 1 (ref) 1 (ref) 
Living in couple 0.98 (0.78 - 1.24) 0.872 0.71 (0.43 - 1.19) 0.199 0.95 (0.63 - 1.44) 0.825 
Born in Switzerland 
No 1 (ref) 1 (ref) 1 (ref) 
Yes 0.99 (0.78 - 1.26) 0.958 0.74 (0.43 - 1.27) 0.276 0.68 (0.44 - 1.04) 0.077 
Smoking status 
Never 1 (ref) 1 (ref) 1 (ref) 
Former 1.45 (1.11 - 1.88) 0.006 1.02 (0.57 - 1.82) 0.941 1.08 (0.68 - 1.71) 0.738 
Current 2.21 (1.66 - 2.93) <0.001 0.79 (0.40 - 1.58) 0.51 1.50 (0.88 - 2.57) 0.135 
p-value for trend <0.001 0.560 0.223 
Physically active 
No 1 (ref) 1 (ref) 1 (ref) 
Yes 0.93 (0.74 - 1.16) 0.506 0.99 (0.58 - 1.69) 0.978 1.24 (0.82 - 1.86) 0.310 
Hypertension 
None 1 (ref) 1 (ref) 1 (ref) 
Already known 2.08 (1.61 - 2.70) <0.001 0.58 (0.32 - 1.07) 0.079 2.48 (1.56 - 3.95) <0.001 
Diagnosed at baseline 1.35 (0.97 - 1.90) 0.076 0.94 (0.39 - 2.24) 0.882 0.79 (0.35 - 1.80) 0.573 
Dyslipidemia 
None 1 (ref.) 1 (ref.) 1 (ref.) 
Already known 1.14 (0.88 - 1.49) 0.313 1.15 (0.62 - 2.12) 0.665 2.22 (1.39 - 3.52) 0.001 
Diagnosed at baseline 1.07 (0.80 - 1.43) 0.660 1.63 (0.85 - 3.15) 0.142 1.6 (0.9 - 2.87) 0.112 
Diabetes 
None 1 (ref) 1 (ref) 1 (ref) 
Already known 2.24 (1.46 - 3.42) <0.001 0.58 (0.18 - 1.84) 0.353 2.60 (1.42 - 4.75) 0.002 
Diagnosed at baseline 3.37 (1.91 - 5.95) <0.001 3.71 (0.58 - 23.7) 0.165 4.38 (1.2 - 16.0) 0.025 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis using 
polytomous logistic regression using the “never” group as reference, using all variables in the table as covariates plus the number of 
medicines at baseline. 
Supplementary table 6: multivariate analysis of the factors associated with changes in polyactive substances (5+ active substances/day) status 
between baseline (2003-2006) and follow-up (2009-2012), Colaus study, Switzerland, 4679 participants. 
Initiation P-value Quitting P-value Maintenance P-value 
N (% total) 404 (8.6) 156 (3.3) 260 (5.6) 
Gender 
Woman 1 (ref) 1 (ref) 1 (ref) 
Man 0.57 (0.45 - 0.72) <0.001 0.69 (0.38 - 1.26) 0.224 0.78 (0.49 - 1.26) 0.313 
Age group 
[35-50[ 1 (ref) 1 (ref) 1 (ref) 
[50-65[ 1.78 (1.37 - 2.32) <0.001 1.35 (0.71 - 2.58) 0.360 1.65 (0.89 - 3.05) 0.109 
[65-75] 2.66 (1.92 - 3.68) <0.001 1.25 (0.57 - 2.74) 0.585 2.62 (1.32 - 5.22) 0.006 
p-value for trend <0.001 0.571 0.003 
BMI categories 
Normal 1 (ref) 1 (ref) 1 (ref) 
Overweight 1.64 (1.28 - 2.10) <0.001 1.15 (0.65 - 2.05) 0.631 1.37 (0.83 - 2.27) 0.213 
Obese 2.00 (1.46 - 2.73) <0.001 1.19 (0.54 - 2.63) 0.666 2.07 (1.12 - 3.82) 0.020 
p-value for trend <0.001 0.575 0.014 
Education 
High 1 (ref.) 1 (ref.) 1 (ref.) 
Middle 1.04 (0.73 - 1.48) 0.825 1.25 (0.59 - 2.65) 0.560 1.95 (0.96 - 3.94) 0.064 
Low 1.19 (0.87 - 1.62) 0.274 1.06 (0.53 - 2.10) 0.871 1.80 (0.95 - 3.42) 0.073 
p-value for trend 0.201 0.986 0.166 
Marital status 
Living alone 1 (ref) 1 (ref) 1 (ref) 
Living in couple 1.03 (0.83 - 1.29) 0.773 0.97 (0.59 - 1.59) 0.898 1.08 (0.71 - 1.64) 0.717 
Born in Switzerland 
No 1 (ref) 1 (ref) 1 (ref) 
Yes 0.97 (0.77 - 1.23) 0.828 0.87 (0.52 - 1.47) 0.600 0.82 (0.53 - 1.28) 0.381 
Smoking status 
Never 1 (ref) 1 (ref) 1 (ref) 
Former 1.52 (1.18 - 1.95) 0.001 0.88 (0.5 - 1.53) 0.649 1.19 (0.74 - 1.91) 0.465 
Current 2.14 (1.63 - 2.81) <0.001 0.87 (0.45 - 1.7) 0.688 1.81 (1.04 - 3.14) 0.035 
p-value for trend <0.001 0.600 0.057 
Physically active 
No 1 (ref) 1 (ref) 1 (ref) 
Yes 0.91 (0.73 - 1.13) 0.391 1.03 (0.62 - 1.72) 0.916 1.30 (0.85 - 1.98) 0.224 
Hypertension 
None 1 (ref) 1 (ref) 1 (ref) 
Already known 2.72 (2.13 - 3.49) <0.001 1.34 (0.75 - 2.38) 0.321 4.1 (2.54 - 6.61) <0.001 
Diagnosed at baseline 1.53 (1.11 - 2.10) 0.009 1.28 (0.55 - 2.96) 0.566 0.89 (0.39 - 2.00) 0.769 
Dyslipidemia 
None 1 (ref.) 1 (ref.) 1 (ref.) 
Already known 1.20 (0.93 - 1.54) 0.155 0.74 (0.41 - 1.33) 0.310 1.50 (0.93 - 2.42) 0.100 
Diagnosed at baseline 0.96 (0.72 - 1.27) 0.761 1.15 (0.60 - 2.18) 0.676 1.17 (0.65 - 2.11) 0.609 
Diabetes 
None 1 (ref) 1 (ref) 1 (ref) 
Already known 2.51 (1.64 - 3.83) <0.001 0.60 (0.21 - 1.77) 0.359 2.60 (1.38 - 4.90) 0.003 
Diagnosed at baseline 3.34 (1.92 - 5.81) <0.001 2.22 (0.36 - 13.9) 0.392 3.13 (0.87 - 11.2) 0.080 
BMI, body mass index. Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis 
using polytomous logistic regression using the “never” group as reference and using all variables in the table as covariates plus the 
number of medicines at baseline. 
